Dr. Brentjens Discusses Potential for CAR T-Cell Therapy in Solid Tumors
January 25th 2018Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the potential for chimeric antigen receptor therapy (CAR) T-cell therapy in solid tumors.
Dr. Andreadis on Developments to CAR T-Cell Therapy
January 23rd 2018Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses developments being made to chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies.
Dr. Andreadis on the Current State of CAR T-Cell Therapy in Lymphoma
January 22nd 2018Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses chimeric antigen receptor (CAR) T-cell therapy in lymphoma.
Dr. Maloney on Targets for CAR T-Cell Therapy
January 19th 2018David Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the success and challenges of chimeric antigen recptor (CAR) T-cell therapy in hematologic malignancies.
Dr. Brentjens on Obstacles with CAR T-Cell Therapy in Hematologic Malignancies
January 17th 2018Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses challenges facing chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies.
Dr. Maloney Discusses Response to JCAR017 CAR T-Cell Therapy
January 11th 2018David Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses responses to the chimeric antigen receptor (CAR) T-cell product JCAR017.
Dr. Andreadis on CAR T-Cell Therapy for Pediatric ALL
December 29th 2017Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the role of chimeric antigen receptor (CAR) T-cell therapy for pediatric patients with acute lymphocytic leukemia (ALL).
Dr Stephen Schuster on Institution Commitments to Deliver CAR T Therapies
December 28th 2017Deciding to administer CAR T-cell therapies is an institutional commitment that requires educating all clinicians who will be involved and partnerships with other organizations, said Stephen Schuster, MD, of the Perelman School of Medicine.
Dr Shannon Maude Discusses Side Effects of CAR T Therapies
December 25th 2017Most primary side effects of CAR T therapies occur early on after treatment and resolve quickly, but there are some that require long-term monitoring, explained Shannon L. Maude, MD, PhD, of The Children's Hospital of Philadelphia.
This Week in Managed Care: December 22, 2017
December 22nd 2017This week, the top managed care stories included the elimination of the Affordable Care Act's individual mandate; a new gene therapy for inherited vision loss that could cost $1 million; and a study found that social isolation can increase the risk of type 2 diabetes.
Dr. Maloney on CAR T-Cell Product in B-Cell Lymphoma
December 19th 2017David Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the preliminary safety data of the chimeric antigen receptor (CAR) T-cell product, JCAR017, in relapsed/refractory aggressive B-cell lymphoma.
Dr. Daver on CAR T-Cell Therapy Approval in Pediatric ALL
November 16th 2017Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the approval of a chimeric antigen receptor (CAR) T-cell therapy in pediatric acute lymphoblastic leukemia.
Dr. Epperla on CAR T-Cell Therapy in MCL
November 15th 2017Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with mantle cell lymphoma (MCL).